Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
7 Hills Pharma, LLC
Eikon Therapeutics
Novartis
GlaxoSmithKline
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
San Raffaele University
VA Office of Research and Development
Radiopharm Theranostics, Ltd
Replimune Inc.
Fudan University
St. Jude Children's Research Hospital
University of Cincinnati
GlaxoSmithKline
Shanghai Zhongshan Hospital
Women's Hospital School Of Medicine Zhejiang University
UNICANCER
ImmunityBio, Inc.
Shanghai Zhongshan Hospital
Sun Yat-sen University
Massive Bio, Inc.
National Cancer Institute (NCI)
Peking Union Medical College Hospital
University of Pittsburgh
Medicenna Therapeutics, Inc.
AIO-Studien-gGmbH
GERCOR - Multidisciplinary Oncology Cooperative Group
Sanford Health
M.D. Anderson Cancer Center
Shattuck Labs, Inc.
WellSpan Health
Sun Yat-sen University
Incyte Corporation
Ohio State University Comprehensive Cancer Center
University of Pittsburgh
Queensland Centre for Gynaecological Cancer
San Raffaele University
Molecular Templates, Inc.
Massachusetts General Hospital
Peking University People's Hospital
West China Hospital
The Hospital for Sick Children
Henan Cancer Hospital
Institut Bergonié
Third Affiliated Hospital, Sun Yat-Sen University
Apollomics (Australia) Pty. Ltd.
National Institutes of Health Clinical Center (CC)
University of Colorado, Denver
Incyte Corporation